Stereotactic body radiotherapy for pancreatic cancer: Analysis of toxicity.

• DOI: 10.1200/jco.2017.35.4_suppl.436
• Publication Date: 2017-03-21T17:08:11Z
• Authors: Subha Perni; Pan Kim; Theodore Yanagihara; Ashish Jani; Christine Chin; Ping Yan; Brian Wolthius; Carl Elliston; Daniela Gidea-Addeo; David Paul Horowitz
• Keywords: 03 medical and health sciences; 0302 clinical medicine; 3. Good health

436 Background: Pancreatic ductal adenocarcinoma (PDAC) carries a poor prognosis, with significant morbidity and mortality from local progression. Radiotherapy can be administered for control, stereotactic body radiotherapy (SBRT) increasingly being utilized. We aim to compare the toxicity of SBRT intensity-modulated (IMRT) in this setting. Methods: A retrospective analysis patients PDAC receiving IMRT or at our institution between April 2011 November 2015 was performed. 81 were identified. Clinical notes reviewed treatment details acute late toxicities. Late data available 62 patients. Toxicity assessed using Common Terminology Criteria Adverse Events version 4.0. Radiology reports assess presence recurrence and/or Results: Median follow-up RT 29 months (95% CI 22-36 months), median survival 25 22-34 months). received 37.5-54 Gy 15-30 fractions. SRBT 19.8-39.6 3-6 45% 29% had failure (p = 0.1329). significantly more likely have Grade ≥2 gastrointestinal (GI) than (RR 1.70; 95% 0.98-2.96, p 0.0489), although one patient stopped due extrahepatic stricture. There no differences GI (67% 2 higher vs. 57%, respectively, 0.4244), died bleeding.IMRT lose weight during RT(Median -0.03% -0.004%, 0.0001) moreEmergency Department (ED) visits after (Range 0-8 0-3, 0.0019). dermatitis, fatigue, hematologic toxicity. Conclusions: Patients locally advanced treated versus toxicity, loss, ED RT, but is relatively tolerable convenient alternative pancreatic cancer.